IPHA•benzinga•
Innate Pharma Granted U.S. FDA Breakthrough Therapy Designation To Lacutamab For Relapsed Or Refractory Sézary Syndrome
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 17, 2025 by benzinga